patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug · antibody

save

ELREXFIO

updated 2mo ago

by $PFE PFIZER INC🔗 ChEMBL

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and neoplasm and 2 investigational indications.

targets

T cell surface glycoprotein CD3Tumor necrosis factor receptor superfamily member 17

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

ELREXFIO

trade names

Elrexfio

generic

ELRANATAMAB

MOA

12.1 Mechanism of Action Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab-bcmm activated T-cells, caused proinflammatory cytokine release, and resulted in multiple myeloma cell lysis.

indication

1 INDICATIONS AND USAGE ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ELREXFIO is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T‑cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 )

ELREXFIO

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside

Trials studying ELREXFIO